期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 9, 期 4, 页码 519-534出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.09.10
关键词
angiogenesis; anti-tenascin antibody; c-met inhibitor; cilengitide; extracellular matrix; glioblastoma; invasion; migration; PI3K inhibitor; scatter factor/hepatocyte growth factor inhibitor; TGF-beta
资金
- Schering-Plough
- Exelixis
- Amgen
- Novartis
- Astra-Zeneca
- Genentech
- Haley/Cairns Brain Tumor Research Fund
- Borhek Brain Tumor Research Fund
Glioblastomas are the most common and lethal form of malignant primary brain tumors. Although some progress has been made, the impact of recent advances in multimodality therapies on clinical outcome has been disappointing, with a median survival of less than 15 months. A major challenge in patients with glioblastomas is the propensity of the tumor to invade into adjacent brain tissue. Invasive tumor cells escape surgical removal and, because of their reduced proliferation rate and increased resistance to apoptosis, they are relatively resistant to radiation therapy and chemotherapy. Recently, there has been important progress in understanding the molecular determinants of glioma invasion and migration. This review will summarize some of the therapeutic strategies for inhibiting invasion in glioblastomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据